The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Let's hope that comes true for all LTs here.
Exactly. "The 12 month price target for Abingdon Health PLC's share price is to rise to 78.00 in the next year from the last price of 10.50". Happy days....
Good luck, Brighty
Woo hoo, from a 56p target to 78p!
Someone out there knows even more than Muck165
https://markets.investorschronicle.co.uk/data/equities/tearsheet/forecasts?s=ABDX:LSE#:~:text=Share%20price%20forecast,the%20last%20price%20of%2010.50.
Don't think they need any big firms circulating round them, to be honest. Reckon they have the potential to be big enough all by themselves.
I am surprised no big firms are circulating , Abingdon have so many different options they are looking into ,some big firm must have noticed this or maybe keeping track of what’s going on,in time a bid may materialise,but at what price.
Another observation…
It would appear that Salignostics have become a client of Sheng Enterprises, a Chinese company helping Israeli companies get a foothold in the Chinese market. More detail can be found here under the March 24 event “ The Israel Medical Device Special Matchmaking Event” - https://www.sheng-cn.com.cn/events-meetings/.
More on Sheng generally here - https://www.sheng-cn.com.cn/
More for awareness really
Please please CY give us some news!
Been showing rapid growth in recent years and been stuck at 10p for a while buying pressure in recent weeks should eventually win a push this upto 20p hoping this week will be the week for that
Just another little observation….
ABDX latest blog was about security of supply chain, written by our COO Mark Jones - https://www.abingdonhealth.com/ensuring-your-critical-components-are-protected-the-importance-of-supply-agreements/
Whist this is undated, it appears to me to be a new news release from a company called Rosti, who have partnered with is for injection moulding.
https://rosti.com/rosti-uk-secures-exciting-new-project-with-abingdon-health/
Just interesting that focus lately has been on supply and security of manufacturing components.
I see Wynbore is still trying to get a foothold..
Set your phasers to stun lol
Goodness, springing upwards week by week. Won't be long now!
In that case we need to get 80p...... so £8m-12m profit to support that price, I guess.
12 months ... (maybe....) :0))
(Just my opinion DYOR etc)
Wyndrum, IIs won't even glance at a stock unless it has a mcap of > £100 mill as there just isn't enough liquidity for their size of dealing.
Closed at 11p today...still on track to have a go at 12p. (Hopefully tomorrow. It would be bullish if it did.)
Hi Muck, yes it all looks to be coming together, and although at the moment, I can't see what the valuation could be, it would seem to be at a substantial premium to where it is now.
I think this is such a small cap that due to its size it HAS to go under the radar of ii's but with a couple more promising RNS's confirming extra sales order/contracts in effect making no more cash raises likely, will cause a re-rate and then as the mkt cap increases so it will then creep on to more analysts spread sheets.
So I wait for the virtuous circle that I believe has actually started (as foretold by the charts! ha ha :0))
atb
Hi Wyn
Agree - getting regulatory approval is like wading through treacle and all sorts of extra requests can delay things. But the point still remains valid - it’s reasonable to think we’re entering a time window when a decision might be made.
And the Times of Israel quoted Krieff last month as saying Salistick is currently being “positioned” in the States.
How approval might directly affect ABDX I don’t know - we’re unlikely to be a US distributor (although that would be amazing!), but we will still be manufacturing.
Hi Muck,
fwiw, but AGL went through the FDA thing. I think (I empasize think), that the FDA have a 150 days also to ask more questions or get more info if they feel they need it, rather than just a 150 day dead line for a decision. If they do request more data or whatever I believe the clock is rest. Again from memory, AGL waited over a year over the 150d days before they eventually succeeded with FDA approval And to be fair it was during covid so there exceptional time delays on the part of the FDA as well, so who knows.....
Just another small observation…
We know that Salignostics got UKCA approval in March 23, and that they also have CE. We also know they had initial meetings with the FDA by at least November 21.
Now, I’m not entirely sure what FDA approval pathway they’d have to follow, and so what additional requirements the FDA might have over and above conformity assessments in the U.K/EU
What I do know is that for a De Novo application, being the pathway for a device with no existing substantial equivalent, the FDA aim to give a decision within 150 days of having all necessary information.
So if we got UKCA in March 23, I think it’s reasonable to think an FDA decision can’t be too far away (assuming there’s been no hiccups!)
Nice steady climb over the past month though, so let's hope the trend continues into the next piece of good news which looks fairly imminent judging from all the fabulous research Muck has been doing.
Just a slight more volume been sold today, tomorrow hopefully trend will reverse.
You're great Muck165! You sure are helpful. Hope youre getting out in the fresh air too as this share will come good when it's ready IMO! Exciting stuff - and just so happy that if newcomers do actually check out the opinions of shareholders on this board, they will find the majority of posts are so positive and forward looking and, as a bonus, so civilised lol .
1. Boots have little pop up that tells you how many times an item has been viewed, and how many times its been added to basket in the last 24 hours. I've been watching this daily (sad I know) since our Vit D and Iron tests launched, and we are consistently ahead of the MHC equivalents, despite no price differential. Boots are selling between 25 and 50 of each product each day, online only.
Loop - - their CEO has been heavily publicising a speaking session he is delivering at the EIT Health Summit on 18-19 April. Perhaps we might get a UKCA announcement before then?
As I say, just little observations...
More good news from the Upfront CEO today
https://www.linkedin.com/posts/gonzaloladreda_timeislife-activity-7183373180240019457-NJE-?utm_source=share&utm_medium=member_desktop
Don’t know what happened there! Just look at the recommendation letter on page 20, which has come from one of the largest medical device manufacturers in the world.
I lied! Last one, promise!
On page 20 of the presentation Upfront show a letter of recommendation from Medtronic, which says “The current stroke penetration rate of of